...
首页> 外文期刊>British journal of nursing: BJN >Central venous access device-related sheaths: a predictor of infective and thrombotic incidence?
【24h】

Central venous access device-related sheaths: a predictor of infective and thrombotic incidence?

机译:中央静脉接入装置相关护套:感染性和血栓形成的预测因子?

获取原文
获取原文并翻译 | 示例

摘要

Central vascular access device (CVAD)-related sheaths, sometimes described as 'fibrin sheaths', may result in minor or significant sequelae, from persistent withdrawal occlusion (PWO) to infective sheaths associated with increased morbidity and mortality. The authors studied 179 patients who underwent isotope scans, where isotope was infused via the CVAD. Isotope was found to bind to the sheaths around the catheters of some patients. The amount of uptake was taken to be an extent to which a sheath had developed around the CVAD. The degree of uptake of isotope was categorised into three groups: low uptake, moderate uptake and high uptake. Patients were then followed up from the date the CVAD was inserted to 12 months after the date of the isotope scan, until the device was removed or to the date the patient died, to identify incidence of infection, thrombosis and PWO. PWO incidence in all levels of uptake was around 5-7%. Bloodstream infection (BSI) incidence for low uptake was 7% (9/130), moderate uptake 10% (3/30) and for patients with significant uptake 16% (3/19). Thrombosis for no uptake was less than 1% (1/130), moderate uptake 7% (2/30), and significant uptake had no incidence of thrombosis. Total complications: no uptake 15%, moderate uptake 23% and significant uptake 21%. This single-centre study showed that patients with isotope-highlighted sheaths experienced higher incidence of infective, thrombotic and total complications.
机译:中央血管接入装置(CVAD) - 有时被描述为“纤维蛋白护套”,可能导致尿液或显着的后遗症,从持续的退出闭塞(PWO)与发病率和死亡率增加相关的感染护套。作者研究了179名接受同位素扫描的患者,其中同位素通过CVAD注入。发现同位素与一些患者的导管周围的护套结合。摄取量被认为是鞘在CVAD周围开发的程度。同位素的摄取程度分为三组:低吸收,中度摄取和高吸收。然后从同位素扫描日期后12个月内插入CVAD到12个月后,直到患者死亡,鉴定感染,血栓形成和PWO的发生率直至给设备去除或者日期。所有摄取水平的PWO发病率约为5-7%。血流感染(BSI)低摄取的发病率为7%(9/130),适度摄取10%(3/30),并为具有显着摄取的患者16%(3/19)。对于不摄取的血栓形成小于1%(1/130),中度摄取7%(2/30),显着摄取没有血栓形成的发生率。总并发症:没有摄取15%,适度摄取23%,显着摄取21%。这种单一中心的研究表明,具有同位素突出显示的护套的患者患有更高的感染性,血栓形成和完全并发症的发病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号